LOARGYS AA-Med Pty Ltd
Product name
LOARGYS
Sponsor
Accepted date
Dec-2025
Active ingredients
pegzilarginase
Proposed indication
LOARGYS (pegzilarginase) is proposed as a treatment for arginase 1 deficiency (ARG1 D), also called hyperargininemia, a rare, inherited metabolic disorder where the body is unable to break down the amino acid arginine. It proposed for use in adults, teenagers, and children aged 2 years and older.
Application type
A (new medicine)
Publication date
Dec-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.